Cannabis and Restless Legs Syndrome
Limited case evidence suggests cannabis may relieve RLS symptoms in some patients; stronger evidence supports standard treatments.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Six published patients and a couple of online surveys is the entire evidence base. That's enough to say 'some people report relief' — not enough to say it works or to recommend it first. Standard RLS treatments (iron if deficient, gabapentin, dopamine agonists) have real trials behind them. If those fail or cause augmentation, cannabis is a reasonable conversation with a sleep specialist; it's not a first-line drug.
Not medical advice
This article is not medical advice. Restless legs syndrome is often a symptom of an underlying medical issue — iron deficiency, kidney disease, medication side effect, or pregnancy — that needs clinical evaluation. If you have RLS symptoms, see a healthcare provider before self-treating with cannabis or any other substance. Cannabis can interact with sedatives, antidepressants, and dopaminergic drugs commonly used to treat RLS. Do not use cannabis as a substitute for a medical workup.
Plain-language summary
Restless legs syndrome (RLS), also called Willis-Ekbom disease, is a neurological condition characterized by an uncomfortable, hard-to-describe urge to move your legs — usually in the evening or at night — that is temporarily relieved by movement. It disrupts sleep and causes daytime fatigue. Strong evidence [1]
Standard treatments include iron supplementation when serum ferritin is low, gabapentin or pregabalin, dopamine agonists (pramipexole, ropinirole, rotigotine), and in severe cases low-dose opioids. Strong evidence [1]
A small number of patients report that cannabis — usually smoked or vaporized flower — relieves their RLS symptoms, sometimes substantially. The published evidence consists of one French case series of six patients, a 2020 survey of an online RLS community, and scattered individual case reports. Weak / limited [2][3] There are no randomized controlled trials. We can say cannabis might help some people with RLS, but we cannot say how often, which cannabinoids matter, what dose works, whether tolerance develops, or how it compares to standard treatments in a controlled setting.
Standard RLS treatments (evidence-based)
Before discussing cannabis, the treatments with strong evidence for RLS are:
Iron repletion when serum ferritin is below ~75 ng/mL Strong evidence [1][5]. This is the first step if not already done. Iron deficiency is the most common modifiable cause of RLS.
Alpha-2-delta ligands — gabapentin enacarbil and pregabalin — are FDA-approved for RLS and have strong trial evidence Strong evidence [1]. Common side effects include sedation, dizziness, and weight gain.
Dopamine agonists (pramipexole, ropinirole, rotigotine) are FDA-approved and effective short-term Strong evidence [1]. A major long-term problem is augmentation: symptoms worsen and occur earlier in the day despite stable dosing, requiring dose escalation or switching drugs. Strong evidence [6]
Low-dose opioids (methadone, oxycodone, codeine) are reserved for refractory cases because of dependence risk, but have strong evidence for symptom control Strong evidence [1].
If you have not had a ferritin level checked recently, that is the first conversation to have with your clinician.
Cannabis evidence: what the literature shows
The case series
The most-cited study is Megelin and Ghorayeb (2017), published in Sleep Medicine: a case series of six RLS patients who used cannabis. Weak / limited [2] All six reported total or near-total symptom relief. Five smoked cannabis flower; one used CBD oil. No control group, no blinding, no long-term follow-up data. These were self-selected patients willing to try cannabis.
Survey data
Ghorayeb (2020) surveyed members of an online RLS community who had tried cannabis. Weak / limited [3] Most reported improvement in symptoms and sleep quality. This is survey data with strong selection bias: people who tried cannabis and got no benefit are unlikely to remain in cannabis discussion groups. We cannot infer effectiveness from a self-selected online survey.
Recent review
Samaha et al. (2023) reviewed the literature on cannabis for RLS and concluded that evidence is limited to case reports and uncontrolled surveys, with no randomized trials, and called for well-designed trials before clinical recommendations. Weak / limited [4]
What we can reasonably conclude from this evidence: A subset of RLS patients reports meaningful subjective relief from inhaled cannabis, with rapid onset suitable for evening symptoms. Whether this represents a direct effect on RLS pathophysiology, a secondary benefit from sleep promotion or anxiety relief, or placebo cannot be distinguished from current data.
What does not have evidence
CBD alone for RLS No data One patient in the Megelin case series used CBD oil and reported benefit. There is no other published evidence specifically testing CBD in RLS. Given that CBD has weak activity at cannabinoid receptors compared to THC, and given the RLS mechanism likely involves dopamine and opioid systems, CBD-only efficacy is speculative.
Topical cannabis for RLS No data RLS is a central nervous system disorder. Topical cannabinoid formulations do not penetrate the blood-brain barrier in meaningful concentrations and are unlikely to be effective.
Specific 'RLS strains' No data Dispensary marketing names and indica/sativa labels do not reliably predict cannabinoid content or clinical effects. Disputed The distinction between "indica" and "sativa" is based on plant morphology, not chemical composition or pharmacology. Strain names are not standardized across producers.
Cannabis reducing objective periodic limb movements on polysomnography No data Patients report symptom improvement subjectively. There is no controlled data on whether cannabis actually reduces the number or duration of periodic limb movements recorded on a sleep study. These are different outcomes — symptom relief and objective movement disorder are not equivalent.
Cannabis as a replacement for workup No data Cannabis does not treat iron deficiency, kidney disease, peripheral neuropathy, or medication-induced RLS. Using cannabis to mask symptoms delays diagnosis of these correctable or important underlying conditions.
What we don't know
Nearly everything that matters for a clinical recommendation remains unstudied:
- Efficacy vs. placebo: No randomized blinded trial has been performed.
- Active cannabinoids: Do both THC and CBD matter? Are minor cannabinoids involved? Current data cannot answer this.
- Dose and titration: No dose-finding studies exist. What dose relieves symptoms? What is the minimal effective dose?
- Tolerance and augmentation: Do patients develop tolerance to cannabis over weeks or months, as they do with dopamine agonists (augmentation)? This is biologically plausible but entirely unstudied.
- Rebound or withdrawal-related worsening: Can daily cannabis use cause rebound or withdrawal-related worsening of RLS — similar to what happens when dopamine agonists are stopped abruptly? This mechanism is theoretically possible but has no published data.
- Interactions with standard RLS drugs: How does cannabis interact pharmacokinetically or pharmacodynamically with gabapentin, dopamine agonists, or opioids? No controlled studies.
- Long-term safety and efficacy: All existing reports are short-term. Do patients maintain benefit? Do side effects emerge?
- Effects in pregnancy-related RLS: RLS is common in the third trimester. Cannabis should be avoided in pregnancy regardless Strong evidence [7], but this population has not been studied.
- Optimal route and timing: Inhaled forms have rapid onset, but optimal timing relative to symptom onset, and whether tolerance differs by route, is not known.
Cannabis vs. standard treatments: comparison
| Treatment | Evidence quality | Symptom onset | Major downside | Evidence of long-term efficacy |
|---|---|---|---|---|
| Iron (if ferritin low) | Strong [1][5] | Weeks to months | Slow; only works if deficiency present | Strong [1] |
| Gabapentin enacarbil / pregabalin | Strong [1] | 1–3 days | Sedation, dizziness, weight gain, cognitive effects | Strong [1] |
| Dopamine agonists (pramipexole, ropinirole) | Strong short-term [1][6] | 1–3 days | Augmentation with prolonged use; impulse-control side effects | Weak long-term due to augmentation [6] |
| Low-dose opioids (methadone, oxycodone) | Strong for refractory RLS [1] | 1–2 hours | Dependence, tolerance, regulatory barriers | Uncertain without long-term RCTs |
| Cannabis (inhaled) | Weak (6 cases, 1 survey) [2][3] | Minutes to 1 hour | Cognitive impairment, dependence potential, no long-term safety data | No long-term data; no RCTs |
Important note: No head-to-head comparisons exist. Patient anecdotes that cannabis works "better than ropinirole" or "faster than gabapentin" are interesting but not evidence in the scientific sense. Superiority claims require controlled trials.
Risks and practical considerations
If you and your clinician decide to explore cannabis for RLS after standard treatments have failed or caused intolerable side effects:
Route of administration Inhaled forms (vaporized flower) have the fastest onset (minutes) and allow easy titration for evening symptom onset. Edibles are slow (1–2 hours), unpredictable in absorption, and a poor match for a symptom that arrives suddenly at bedtime and needs rapid relief.
Dosing Start with a low dose. RLS patients are often older, often taking other CNS-active medications (gabapentin, opioids, benzodiazepines), and are at higher risk of adverse effects. There is no published guidance on optimal dosing.
Drug interactions Cannabis can amplify sedation and cognitive impairment when combined with gabapentin, pregabalin, opioids, benzodiazepines, and other CNS depressants. See Cannabis and Polypharmacy Risks for more detail.
Daily use and dependence About 1 in 10 cannabis users develop cannabis use disorder (dependence); rates are higher in daily users. Strong evidence [8] Heavy daily cannabis use disrupts sleep architecture, particularly REM sleep, which may worsen the sleep problems RLS patients are trying to solve. Abrupt cessation after prolonged daily use can trigger rebound insomnia — the opposite of therapeutic.
Cognitive effects and driving Cannabis impairs next-day cognitive function, especially with edibles or high doses. If you use cannabis in the evening for RLS, assess whether you are safe to drive the following morning.
Do not replace medical workup Cannabis does not fix iron deficiency, reverse kidney disease, treat neuropathy, or eliminate medication-induced RLS. Using cannabis to mask symptoms delays diagnosis of treatable or important underlying causes.
Bottom line
Cannabis for RLS is a reasonable conversation with a sleep specialist if standard treatments (iron repletion, gabapentin, dopamine agonists) have been tried, have failed, or have caused augmentation or intolerable side effects. The evidence is weak — six published patients and online surveys — but these patients did report meaningful relief, and cannabis does not pose the long-term augmentation problem that dopamine agonists do.
However, cannabis is not a first-line treatment. It has no proven superiority to standard drugs, causes cognitive impairment, carries dependence risk with daily use, and long-term efficacy and safety are unknown. Anyone telling you the evidence is strong or that cannabis is better than FDA-approved options is overselling the data.
Any trial of cannabis should be combined with continued monitoring of ferritin and kidney function, ongoing use of effective standard treatments if needed, and careful attention to drug interactions and sleep quality. If cannabis is being considered for pregnancy-related RLS, it should be avoided; cannabis and pregnancy risks are well-established.
Sources
- Peer-reviewed Silber MH, Buchfuhrer MJ, Earley CJ, et al. The Management of Restless Legs Syndrome: An Updated Algorithm. Mayo Clinic Proceedings. 2021;96(7):1921-1937.
- Peer-reviewed Megelin T, Ghorayeb I. Cannabis for restless legs syndrome: a report of six patients. Sleep Medicine. 2017;36:182-183.
- Peer-reviewed Ghorayeb I. More evidence of cannabis efficacy in restless legs syndrome. Sleep and Breathing. 2020;24(1):277-279.
- Peer-reviewed Samaha D, Kandiah T, Zimmerman D, Burns KD. Cannabis use in restless legs syndrome: a scoping review. Sleep Medicine Reviews. 2023;72:101806.
- Peer-reviewed Allen RP, Picchietti DL, Auerbach M, et al. Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: review of the literature and practice parameters. Sleep Medicine. 2018;41:27-44.
- Peer-reviewed Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG and EURLSSG. Sleep Medicine. 2016;21:1-11.
- Government American College of Obstetricians and Gynecologists. Committee Opinion No. 722: Marijuana Use During Pregnancy and Lactation. 2017 (reaffirmed 2021).
- Peer-reviewed Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235-1242.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis and Pregnancy: Risks and Evidence — Medical consensus against cannabis use in pregnancy based on fetal exposure and growth res...
- Cannabis Withdrawal Syndrome — Real but not life-threatening withdrawal after heavy regular cannabis use.
- THC Dose and Anxiety — Low doses may reduce acute anxiety; higher doses increase it. Evidence is limited, risks a...